RedHill Biopharma’s Yeliva Gets $300k COVID-19 Grant from Pennsylvania

Redhill Biopharma’s Yeliva (opaganib) was chosen for a $300,000 grant from the state of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program.

The grant covers preclinical research that will examine the drug’s ability to suppress the extent and duration of COVID-19-related acute respiratory distress syndrome. It was awarded to RedHill’s partner, Apogee Biotechnology, which will conduct the research using the state funding.

Yeliva is currently in mid-to-late stage testing globally for hospitalized patients with severe COVID-19 pneumonia who require supplemental oxygen.